Leponex

Clozapine, the active ingredient in Leponex, is an atypical antipsychotic presented as an oral formulation for oral use. It is indicated for patients with treatment‑resistant schizophrenia and schizoaffective disorder who have not responded adequately to other therapies.

GNH USA supplies Leponex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clozapine is an atypical antipsychotic used in the management of serious psychotic disorders that are resistant to standard treatment. - Treatment‑resistant schizophrenia: reduces psychotic symptoms in patients who have not responded to other antipsychotics. - Schizoaffective disorder: helps control both mood and psychotic features in this combined condition. - Persistent psychotic symptoms: provides benefit when alternative agents have failed.

Clozapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation: feeling unusually drowsy or sleepy. - Weight gain: increase in body weight over time. - Hypersalivation: excessive production of saliva. - Constipation: reduced bowel movements. - Dizziness: light‑headed sensation, especially when standing. - Tachycardia: elevated heart rate.

Serious or Rare Side Effects: - Agranulocytosis: severe drop in white blood cells requiring regular monitoring. - Myocarditis: inflammation of the heart muscle. - Seizures: heightened risk, particularly at higher doses. - Orthostatic hypotension: sudden blood pressure drop upon standing. - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Severe constipation leading to ileus: potentially dangerous bowel obstruction.

Clozapine therapy requires careful monitoring and specific safety measures. - Blood monitoring: perform regular complete blood counts to detect agranulocytosis early. - Cardiovascular assessment: evaluate for myocarditis and cardiomyopathy before and during treatment. - Seizure risk: monitor patients with a history of seizures and adjust dose if needed. - Metabolic monitoring: check weight, glucose, and lipid levels periodically. - Drug interactions: avoid concurrent use with strong CYP1A2 inhibitors without dose adjustment. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Clozapine interacts with several medicines that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): can markedly increase clozapine concentrations. - CNS depressants (e.g., benzodiazepines): may enhance sedation and respiratory depression. - Drugs causing agranulocytosis (e.g., carbamazepine): increase risk of blood dyscrasias.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce clozapine efficacy. - Anticholinergic agents: can worsen constipation. - QT‑prolonging drugs: monitor ECG for cardiac rhythm changes.